Prognosis
FDA Leans Toward Authorizing Moderna Booster at a Half Dose
- Pfizer shot already approved to provide new virus shield
- Decision would further widen booster campaign as delta rages
This article is for subscribers only.
The U.S. Food and Drug Administration is leaning toward authorizing half-dose booster shots of the Moderna Inc. coronavirus vaccine, satisfied that it’s effective in shoring up protection, people familiar with the matter said.
The authorization would set the stage to further widen the U.S. booster campaign after earlier authorization of the Pfizer Inc.-BioNTech SE shot. About 170 million fully vaccinated people in the U.S. received the Moderna or Pfizer shots, or 92% of the total inoculated so far.